Rosenthal, Victor D., Yin, Ruijie, Nercelles, Patricio, Rivera-Molina, Sara E., Jyoti, Somani, Dongol, Reshma, Aguilar-De-Moros, Daisy, Tumu, Nellie, Alarcon-Rua, Johana, Stagnaro, Juan P., Alkhawaja, Safaa, Jimenez-Alvarez, Luisa F., Cano-Medina, Yuliana A., Valderrama-Beltran, Sandra L., Henao-Rodas, Claudia M., Zuniga-Chavarria, Maria A., El-Kholy, Amani, Agha, Hala Mounir, Sahu, Suneeta, and Anusandhan, Siksha O.
Reporting on the International Nosocomial Infection Control Consortium study results from 2015 to 2020, conducted in 630 intensive care units across 123 cities in 45 countries spanning Africa, Asia, Eastern Europe, Latin America, and the Middle East. Prospective intensive care unit patient data collected via International Nosocomial Infection Control Consortium Surveillance Online System. Centers for Disease Control and Prevention/National Health Care Safety Network definitions applied for device-associated health care–associated infections (DA-HAI). We gathered data from 204,770 patients, 1,480,620 patient days, 936,976 central line (CL)-days, 637,850 mechanical ventilators (MV)-days, and 1,005,589 urinary catheter (UC)-days. Our results showed 4,270 CL-associated bloodstream infections, 7,635 ventilator-associated pneumonia, and 3,005 UC-associated urinary tract infections. The combined rates of DA-HAIs were 7.28%, and 10.07 DA-HAIs per 1,000 patient days. CL-associated bloodstream infections occurred at 4.55 per 1,000 CL-days, ventilator-associated pneumonias at 11.96 per 1,000 MV-days, and UC-associated urinary tract infections at 2.91 per 1,000 UC days. In terms of resistance, Pseudomonas aeruginosa showed 50.73% resistance to imipenem, 44.99% to ceftazidime, 37.95% to ciprofloxacin, and 34.05% to amikacin. Meanwhile, Klebsiella spp had resistance rates of 48.29% to imipenem, 72.03% to ceftazidime, 61.78% to ciprofloxacin, and 40.32% to amikacin. Coagulase-negative Staphylococci and Staphylococcus aureus displayed oxacillin resistance in 81.33% and 53.83% of cases, respectively. The high rates of DA-HAI and bacterial resistance emphasize the ongoing need for continued efforts to control them. • The objective of this study is to identify rates of HAIs in limited resources countries. • Prospective cohort study over 6 years collected data 204,770 patients from 45 Countries. • The combined rates of HAIs were 7.28%, and 10.07 DA-HAIs per 1000 patient-days. • CLABSI rate 4.55/1,000 CL-days, VAP 1.96/1,000 MV-days, CAUTI 2.91/1,000 UC-days. • P aeruginosa showed 50.73% resistance to imipenem, and 44.99% to ceftazidime. [ABSTRACT FROM AUTHOR]